Morgan Stanley analyst Sean Laaman maintained a Buy rating on Halozyme yesterday and set a price target of $80.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sean Laaman has given his Buy rating due to a combination of factors that highlight Halozyme’s strong financial performance and potential for future growth. Since the beginning of 2025, Halozyme has increased its revenue and EPS guidance significantly, with revenue now projected to be 11% higher and EPS 20% higher than initial estimates. This upward revision is attributed to the better-than-expected performance of partnered products and effective cost management.
Despite these upgrades, the long-term guidance for 2026-2028 has not yet been adjusted, but there is an expectation for future revisions as key products continue to perform well. Laaman’s analysis also suggests that the company’s strong cash flow and high EBITDA margins are underappreciated by the market, indicating further growth potential. While regulatory risks remain, particularly concerning CMS draft guidance, the overall outlook for Halozyme appears positive, justifying the Buy rating.
According to TipRanks, Laaman is a 4-star analyst with an average return of 3.9% and a 58.92% success rate. Laaman covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Halozyme, and BioMarin Pharmaceutical.
In another report released on August 14, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $74.00 price target.